ZYTIGA® (abiraterone acetate)

NOW AVAILABLE

ZYTIGA®(ABIRATERONE ACETATE)

500 MG FILM-COATED TABLETS

ZYTIGA® (abiraterone acetate) in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Consider what 730 fewer tablets* a year could mean for your patients with mCRPC.

See Prescribing Information for updated information.

VIEW PRESCRIBING INFORMATION

Efficacy & Safety

Efficacy & Safety
  • Final analysis of the pivotal Phase 3 study.
  • Co-primary and secondary endpoints data.
  • Established safety and tolerability profile.
  • Discontinuation criteria noted in the COU-AA-302 Study.

Dosing & Monitoring

  • ZYTIGA® recommended dosage and administration.
  • Dose modification guidelines.
  • Patient monitoring considerations and schedule. 

Support & Resources

Support & Resources
  • Comprehensive access support for your patients. 
  • Identifying cost support options according to your patient’s needs.
  • Helpful resources for your patients and their loved ones.

Janssen Oncology

The Janssen Commitment

For more than 30 years, Janssen Biotech, Inc., has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease.